



aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results

March 7, 2022

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update after the market close on Monday, March 14, 2022. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:

Monday, March 14th @ 5:00 p.m. EDT / 2:00 p.m. PDT

Domestic: 844-358-9116

International: 209-905-5951

Conference ID: 3686825

Webcast: <http://investors.atyrpharma.com/events-and-webcasts>

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit <http://www.atyrpharma.com>.

Contact:

Ashlee Dunston

Director, Investor Relations and Corporate Communications

adunston@atyrpharma.com

Source: aTyr Pharma, Inc.